Rein Therapeutics, Inc. (RNTX) stock
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.00 (-0.31%)
Close on Nov 18, 2026Market cap $30.65MP/E –Yield 0.00%
Rein Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Rein Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$49.46M. For fiscal 2025 it was -$50.63M. The highest annual figure on record is -$12.89M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.63M | – |
| FY2024 | Dec 31, 2024 | -$65.11M | – |
| FY2023 | Dec 31, 2023 | -$16.28M | – |
| FY2022 | Dec 31, 2022 | -$27.65M | – |
| FY2021 | Dec 31, 2021 | -$26.61M | – |
| FY2020 | Dec 31, 2020 | -$20.50M | – |
| FY2019 | Dec 31, 2019 | -$29.96M | – |
| FY2018 | Dec 31, 2018 | -$31.90M | – |
| FY2017 | Dec 31, 2017 | -$23.01M | – |
| FY2016 | Dec 31, 2016 | -$18.17M | – |
| FY2015 | Dec 31, 2015 | -$12.89M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$32.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.87M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$42.80M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.21M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.01M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.04M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.82M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.79M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.99M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.19M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.03M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.40M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.92M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.38M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.31M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.98M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.50M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.66M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.76M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.04M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.43M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.95M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.59M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.45M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.23M | – |
See a number that looks wrong?